PURPOSE: Increased bone resorption is a hallmark of multiple myeloma and a result of excessive osteoclast activation. Recently, the receptor activator of NF-kappaB ligand (RANKL) was found to be the critical factor for osteoclastogenesis. Studies showed that myeloma cells induce RANKL expression in bone marrow stromal cells, but it remained a controversy whether myeloma cells directly express RANKL. METHODS: Therefore, we analyzed the expression of RANKL mRNA in freshly isolated CD138 positive plasma cells from patients with multiple myeloma and osteolytic bone lesions, using three different primer pairs against human RANKL. RESULTS: RANKL mRNA could be detected in bone marrow plasma cells from myeloma patients with osteolytic myeloma bone disease. CONCLUSIONS: These findings show that myeloma cells directly express RANKL and indicate that specific blockade of RANKL may be an effective treatment for myeloma bone disease.
PURPOSE: Increased bone resorption is a hallmark of multiple myeloma and a result of excessive osteoclast activation. Recently, the receptor activator of NF-kappaB ligand (RANKL) was found to be the critical factor for osteoclastogenesis. Studies showed that myeloma cells induce RANKL expression in bone marrow stromal cells, but it remained a controversy whether myeloma cells directly express RANKL. METHODS: Therefore, we analyzed the expression of RANKL mRNA in freshly isolated CD138 positive plasma cells from patients with multiple myeloma and osteolytic bone lesions, using three different primer pairs against humanRANKL. RESULTS:RANKL mRNA could be detected in bone marrow plasma cells from myelomapatients with osteolytic myeloma bone disease. CONCLUSIONS: These findings show that myeloma cells directly express RANKL and indicate that specific blockade of RANKL may be an effective treatment for myeloma bone disease.
Authors: Ulrike Heider; Corinna Langelotz; Christian Jakob; Ivana Zavrski; Claudia Fleissner; Jan Eucker; Kurt Possinger; Lorenz C Hofbauer; Orhan Sezer Journal: Clin Cancer Res Date: 2003-04 Impact factor: 12.531
Authors: P I Croucher; C M Shipman; J Lippitt; M Perry; K Asosingh; A Hijzen; A C Brabbs; E J van Beek; I Holen; T M Skerry; C R Dunstan; G R Russell; B Van Camp; K Vanderkerken Journal: Blood Date: 2001-12-15 Impact factor: 22.113
Authors: T Nakashima; Y Kobayashi; S Yamasaki; A Kawakami; K Eguchi; H Sasaki; H Sakai Journal: Biochem Biophys Res Commun Date: 2000-09-07 Impact factor: 3.575
Authors: Ivana Zavrski; Cord Naujokat; Kathrin Niemöller; Christian Jakob; Ulrike Heider; Corinna Langelotz; Claudia Fleissner; Jan Eucker; Kurt Possinger; Orhan Sezer Journal: J Cancer Res Clin Oncol Date: 2003-07-08 Impact factor: 4.553
Authors: Jean-Jacques Body; Philip Greipp; Robert E Coleman; Thierry Facon; Filip Geurs; Jean-Paul Fermand; Jean-Luc Harousseau; Allan Lipton; Xavier Mariette; Catherine D Williams; Arline Nakanishi; Donna Holloway; Steven W Martin; Colin R Dunstan; Pirow J Bekker Journal: Cancer Date: 2003-02-01 Impact factor: 6.860
Authors: Melda Onal; Jinhu Xiong; Xinrong Chen; Jeff D Thostenson; Maria Almeida; Stavros C Manolagas; Charles A O'Brien Journal: J Biol Chem Date: 2012-07-10 Impact factor: 5.157
Authors: C Botta; M T Di Martino; D Ciliberto; M Cucè; P Correale; M Rossi; P Tagliaferri; P Tassone Journal: Blood Cancer J Date: 2016-12-16 Impact factor: 11.037
Authors: Stephan Blüml; Kathleen McKeever; Rachel Ettinger; Josef Smolen; Ronald Herbst Journal: Arthritis Res Ther Date: 2013-04-04 Impact factor: 5.156